{
  "id": 19778840,
  "title": "Cytokinetics director B. Lynne Parshall sells $273,634 in shares",
  "url": "https://urgent.news/2026/11/13/cytokinetics-director-b-lynne-parshall-sells-273-634-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T08:16:21.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-director-b-lynne-parshall-sells-273634-in-shares-93CH-5024399"
  },
  "original_language": "en",
  "account": "B. Lynne Parshall, a director at Cytokinetics Inc., sold 5,000 shares of common stock valued at $273,634 on November 9, 2026, according to a regulatory filing. This sale comprised two separate transactions: the first involved the sale of 2,445 shares at a weighted average price of $54.17 per share, while the second entailed the sale of 2,555 shares at a weighted average price of $55.26 per share. These transactions resulted in the disposition of approximately $132,448 and $141,195, respectively. Following these sales, Ms. Parshall still holds 5,784 shares of Cytokinetics common stock. Notably, Cytokinetics' stock is currently trading at $56.16, which is only slightly above its 52-week low of $53.55. Despite this insider sale, the company's stock appears undervalued based on market conditions, with a market capitalization of $7.82 billion.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}